Press Release
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
Aug 05, 2021
“I am pleased with the progress we have made this quarter across multiple fronts. We are on track with istaroxime, our lead clinical product candidate, as we continue to enroll patients in our phase 2 global study for the treatment of early cardiogenic shock. We are also advancing study start up activities for the next trial with istaroxime in acute heart failure that will build upon our two previous successful phase 2 trials. Our second current active clinical program is a phase 2 study of lucinactant in patients with COVID-19 associated lung injury and Acute Respiratory Distress Syndrome,” said Craig Fraser, President and Chief Executive Officer of Windtree. “With data in both phase 2 trials expected later this year, we are preparing for these important potential value inflection readouts. In addition, we are actively engaging with potential partners and remain opportunistic about business development prospects. Our balance sheet is strong and leaves us well-capitalized to execute on our ongoing clinical and regulatory milestones.”
Key Business and Financial Updates
- Progressed in the Company’s lead program for istaroxime in the treatment of early cardiogenic shock due to heart failure characterized by very low blood pressure and risk for hypo-perfusion to critical organs. This study is designed to build upon the phase 2 program where data showed istaroxime to improve cardiac function and dose related increases in systolic blood pressure. The Company currently has 12 participating trial sites, with data anticipated in the fourth quarter of 2021.
- Continued advancement of clinical trial of lucinactant for the treatment of COVID-19 associated lung injury (COVID-19 ARDS, acute respiratory distress syndrome). Given the changing patterns of COVID-19 due to both vaccines and variants, the Company is expanding the study to include select sites in
Argentina where case counts and the number of severe COVID-19 patients in respiratory failure are high. Data in this phase 2 study is anticipated in the fourth quarter of 2021.
- Continued to advance multiple business development activities, including exploring regional based licensing with istaroxime, specifically in
Asia , to support clinical development costs and activities as well as with the SERCA2a activators globally for development in chronic heart failure.
- Through the process of engaging with potential licensees, the Company recognized that to secure an out-licensing deal for rostafuroxin, an additional small clinical study would need to be conducted. Given that rostafuroxin is outside the current focus for development and investment, the Company is seeking a partner to conduct the additional clinical trial in addition to out-licensing opportunities for this program. Consequently, the Company lowered its rostafuroxin intangible asset value as described below.
- Filed a
Track One prioritized patent application with theU.S. Patent and Trademark Office for istaroxime, which was previously filed under the Patent Cooperation Treaty. Under the Track One program, the new istaroxime patent is expected to receive review and final disposition within a year of priority status being granted, rather than the customary three-year examination for non-prioritized examinations.
- Announced
Diane Carman , Esq. as Senior Vice President and General Counsel. A veteran senior executive,Ms. Carman brings over two decades of successful experience working in the life sciences and other highly regulated industries.
- Presented at the
Ladenburg Thalmann 2021Healthcare Conference and Access toGiving Virtual Investor Conference .
Select Financial Results for the Second Quarter ended
For the second quarter ended
Research and development expenses were
General and administrative expenses for the second quarter of 2021 were
The Company reported a net loss of
As of
Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended
About
For more information, please visit the Company's website at www.windtreetx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company's clinical trials or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime, KL4 surfactant and the Company's other product candidates; the Company's ability to secure significant additional capital as and when needed; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol delivery systems (ADS) and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company's product candidates, if approved. These and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the
Contact Information:
212.915.3820 or monique@lifesciadvisors.com
Media contact:
646.876.5868 or amielach@lifescicomms.com
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 29,965 | $ | 16,930 | ||||
| Prepaid expenses and other current assets | 2,329 | 1,188 | ||||||
| Total current assets | 32,294 | 18,118 | ||||||
| Property and equipment, net | 834 | 924 | ||||||
| Restricted cash | 154 | 154 | ||||||
| Operating lease right-of-use assets | 2,581 | 917 | ||||||
| Intangible assets | 39,320 | 77,090 | ||||||
| 15,682 | 15,682 | |||||||
| Total assets | $ | 90,865 | $ | 112,885 | ||||
| LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 288 | $ | 1,161 | ||||
| Accrued expenses | 3,111 | 3,813 | ||||||
| Operating lease liabilities - current portion | 336 | 805 | ||||||
| Loans payable - current portion | 1,175 | 352 | ||||||
| Total current liabilities | 4,910 | 6,131 | ||||||
| Operating lease liabilities - non-current portion | 2,318 | 201 | ||||||
| Loans payable - non-current portion | - | 2,423 | ||||||
| Restructured debt liability - contingent milestone payments | 15,000 | 15,000 | ||||||
| Other liabilities | 3,200 | 2,800 | ||||||
| Deferred tax liabilities | 8,674 | 16,778 | ||||||
| Total liabilities | 34,102 | 43,333 | ||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, |
- | - | ||||||
| Common stock, |
27 | 17 | ||||||
| Additional paid-in capital | 823,828 | 790,277 | ||||||
| Accumulated deficit | (764,038 | ) | (717,688 | ) | ||||
| (3,054 | ) | (3,054 | ) | |||||
| Total stockholders’ equity | 56,763 | 69,552 | ||||||
| Total liabilities & stockholders’ equity | $ | 90,865 | $ | 112,885 | ||||
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Expenses: | ||||||||||||||||
| Research and development | $ | 4,221 | $ | 4,495 | $ | 8,631 | $ | 7,956 | ||||||||
| General and administrative | 3,371 | 3,453 | 8,040 | 6,695 | ||||||||||||
| Loss on impairment of intangible assets | 37,770 | - | 37,770 | - | ||||||||||||
| Total operating expenses | 45,362 | 7,948 | 54,441 | 14,651 | ||||||||||||
| Operating loss | (45,362 | ) | (7,948 | ) | (54,441 | ) | (14,651 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 39 | 5 | 89 | 94 | ||||||||||||
| Interest expense | (46 | ) | (31 | ) | (87 | ) | (75 | ) | ||||||||
| Other (expense), net | (352 | ) | (1,584 | ) | (243 | ) | (1,460 | ) | ||||||||
| Total other (expense), net | (359 | ) | (1,610 | ) | (241 | ) | (1,441 | ) | ||||||||
| Loss before income taxes | (45,721 | ) | (9,558 | ) | (54,682 | ) | (16,092 | ) | ||||||||
| Income tax benefit | 8,332 | - | 8,332 | - | ||||||||||||
| Net loss | $ | (37,389 | ) | $ | (9,558 | ) | $ | (46,350 | ) | $ | (16,092 | ) | ||||
| Net loss per common share | ||||||||||||||||
| Basic and diluted | $ | (1.42 | ) | $ | (0.63 | ) | $ | (2.10 | ) | $ | (1.12 | ) | ||||
| Weighted average number of common shares outstanding | ||||||||||||||||
| Basic and diluted | 26,350 | 15,091 | 22,047 | 14,394 | ||||||||||||
Source: Windtree Therapeutics